InDex Pharmaceuticals Holding
0,387 SEK +1,31%InDex Pharmaceuticals is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is in late-stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent-protected discovery stage substances, so-called DNA-based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases. InDex is based in Stockholm, Sweden. The company’s shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm.
Lue lisääAnalyst
Viimeisimmät videot
Pörssikalenteri
Suurimmat omistajatLähde: Millistream Market Data AB
Omistaja | Osuus | Ääniä |
---|---|---|
Linc AB | 13,1 % | 13,1 % |
Fjärde AP-Fonden | 9,8 % | 9,8 % |
Inderes Premium
Tämä sisältö on vain Inderes Premium -käyttäjille.
Index Pharmaceuticals: InDex Pharmaceuticals brings forward the publication of the interim report for Q1 2024
Index Pharmaceuticals: InDex Pharmaceuticals provides a company update
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.